The Live biotherapeutic/Microbiome Based Therapeutics Market on a global scale was estimated at USD 73.25 Bn in 2024 and is set to attain USD 142.81 Bn by 2034, with a projected CAGR of 7.04% between 2025 and 2034.
At its core, Live biotherapeutic/Microbiome Based Therapeutics pertains to landscape are mountingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Live biotherapeutic/Microbiome Based Therapeutics Market Snapshot
Chapter 4. Global Live biotherapeutic/Microbiome Based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Live biotherapeutic/Microbiome Based Therapeutics Market Industry Trends
4.10. Global Live biotherapeutic/Microbiome Based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. VOWST (SER-109)
5.2.2. REBYOTA
5.2.3. Visbiome
5.2.4. Other Pipeline Products
Chapter 6. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 2: By Route of Administration, Estimates & Trend Analysis
6.1. Market Share by Route of Administration, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
6.2.1. Oral Therapeutics
6.2.2. Rectal Therapeutics
Chapter 7. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 3: Target Disease Indication, Estimates & Trend Analysis
7.1. Market Share by Target Disease Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Disease Indication:
7.2.1. Recurrent C. Difficile Infection
7.2.2. Dietary management of microbial imbalance
7.2.3. Other Indications
Chapter 8. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
8.2.1. Direct Sales
8.2.2. Pharmacies
8.2.3. Online Platforms
Chapter 9. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
9.2.1. Healthcare Facilities
9.2.2. Home Healthcare
Chapter 10. Live biotherapeutic/Microbiome Based Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Live biotherapeutic/Microbiome Based Therapeutics Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.3. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.2.4. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.2.5. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.2.6. North America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.3. Europe
10.3.1. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.3. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.3.4. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.3.5. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3.6. Europe Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.3. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.4.4. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.4.5. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4.6. Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.5. Latin America
10.5.1. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.3. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.5.4. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.5.5. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5.6. Latin America Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.6.3. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route Of Administration, 2021-2034
10.6.4. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indication, 2021-2034
10.6.5. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6.6. Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Seres Therapeutics, Inc.
11.2.1.1. Business Overview
11.2.1.2. Key Solution/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. 4D Pharma
11.2.3. Adiso Therapeutics
11.2.4. Alveolus Bio Inc
11.2.5. AOBiome Therapeutics, Inc.
11.2.6. Assembly Biosciences
11.2.7. Azitra
11.2.8. Biomica
11.2.9. Destiny Pharma
11.2.10. Destiny Pharma plc
11.2.11. EnteroBiotix Limited
11.2.12. Finch Therapeutics
11.2.13. Infant Bacterial Therapeutics AB
11.2.14. MaaT Pharma
11.2.15. Microbiotica
11.2.16. OSEL INC.
11.2.17. OxThera
11.2.18. Scioto Biosciences, Inc.
11.2.19. Second Genome
11.2.20. Seres Therapeutics
11.2.21. Servatus Limited
11.2.22. Siolta Therapeutics
11.2.23. Vedanta Biosciences
11.2.24. YSOPIA Bioscience
11.2.25. Other prominent player